Ekso Bionics Holdings, Inc. reported an insider purchase by Chief Operating Officer Jason C. Jones on March 16, 2026. Jones acquired 1,308 shares of common stock at a price of $11.85 per share, for a total consideration of $15,499. The acquisition was executed indirectly through a 401(k) account.
At the time of the filing, Ekso's shares were trading at $10.54, a level that reflects an 8.8% decline over the preceding week. Over a longer horizon, the company’s equity has returned 56% over the last year.
Following the transaction, Jones' holdings stand at 25,621 shares owned directly and 4,449 shares owned indirectly.
Separately, InvestingPro’s analysis cited in the company filing indicates that Ekso’s stock appears overvalued relative to its Fair Value, with additional detail available in the Pro Research Report.
Beyond the insider purchase, Ekso announced a private placement transaction with an aggregate value of approximately $5.9 million. The placement consists of the sale of 5,852 shares of Series B Preferred Stock at a stated value of $1,000 per share. The financing package also includes warrants that could be exercised to purchase up to 355,960 shares of common stock.
In a separate strategic move, Ekso entered into a non-binding merger agreement with Applied Digital Cloud, a business segment of Applied Digital, to create a combined entity named ChronoScale Corporation. The proposed combination would pair Applied Digital’s cloud computing operations with Ekso’s business to target artificial intelligence workloads. Under the terms disclosed, Applied Digital would hold roughly 97% ownership of the new company if the transaction proceeds as outlined. The merger is expected to close in the first half of 2026, subject to the necessary approvals and customary closing conditions.
Following the announcement of the proposed merger, H.C. Wainwright revised its rating on Ekso’s stock from Buy to Neutral.
These developments - an insider purchase of modest size, a preferred-stock private placement with sizeable warrant coverage, and a potential merger that would leave Applied Digital with a dominant ownership stake - together highlight a period of material corporate transition for Ekso Bionics. The company and its investors face a sequence of approval and execution risks tied to the proposed transaction and the capital structure changes implied by the financing package.